Published in Medical Letter on the CDC and FDA, December 17th, 2006
"We have examined the propensity of tigecycline to induce CDI using a human gut model. We used a three-stage chemostat human gut model to study the effects of tigecycline on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.